Related Experiment Video
Updated: Jul 31, 2025
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Fasudil promotes polyploidization of megakaryoblasts in an acute megakaryocyte leukemia model
Binghong He1, Chen Wang1, Jiajia Niu1
1Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing, 100875, China.
Abstract:
Acute megakaryocytic leukemia (AMKL) is a rare neoplasm caused by abnormal megakaryoblasts. Megakaryoblasts keep dividing and avoid undergoing polyploidization to escape maturation. Small-molecule probes inducing polyploidization of megakaryocytic leukemia cells accelerate the differentiation of megakaryocytes. This study aims to determine that Rho kinase (ROCK) inhibition on megakaryoblasts enhances polyploidization and the inhibition of ROCK1 by fasudil benefits AMKL mice. The study investigated fasudil on the megakaryoblast cells in vitro and in vivo. With the differentiation and apoptosis induction, fasudil was used to treat 6133/MPLW515L mice, and the differentiation level was evaluated. Fasudil could reduce proliferation and promote the polyploidization of megakaryoblasts. Meanwhile, fasudil reduced the disease burden of 6133/MPLW515L AMKL mice at a dose that is safe for healthy mice. Combination therapy of ROCK1 inhibitor fasudil and reported clinical AURKA inhibitor MLN8237 achieved a better antileukemia effect in vivo, which alleviated hepatosplenomegaly and promoted the differentiation of megakaryoblast cells. ROCK1 inhibitor fasudil is a good proliferation inhibitor and polyploidization inducer of megakaryoblast cells and might be a novel rationale for clinical AMKL treatment.
Insights
Fasudil, a ROCK1 inhibitor, stops acute megakaryocytic leukemia (AMKL) cell division and promotes maturation. This drug shows promise as a novel treatment for AMKL by reducing disease burden and enhancing cell differentiation.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute megakaryocytic leukemia (AMKL) is characterized by abnormal megakaryoblasts that resist maturation.
- Megakaryoblast proliferation and lack of polyploidization contribute to leukemogenesis.
- Targeting pathways that induce megakaryoblast differentiation offers a potential therapeutic strategy.
Purpose of the Study:
- To investigate the effect of Rho kinase (ROCK) inhibition on megakaryoblast polyploidization and differentiation.
- To evaluate the therapeutic potential of the ROCK1 inhibitor fasudil in a mouse model of AMKL.
Main Methods:
- In vitro studies on megakaryoblast cell lines to assess fasudil's impact on proliferation and polyploidization.
- In vivo studies using 6133/MPLW515L mice with AMKL treated with fasudil.
- Evaluation of differentiation levels, apoptosis, and disease burden in treated mice.
- Combination therapy assessment with fasudil and an AURKA inhibitor (MLN8237).
Main Results:
- Fasudil significantly reduced megakaryoblast proliferation and induced polyploidization in vitro.
- In vivo, fasudil treatment decreased the disease burden in AMKL mice at safe dosages.
- Combination therapy with fasudil and MLN8237 demonstrated enhanced anti-leukemia effects, reducing hepatosplenomegaly and promoting differentiation.
Conclusions:
- ROCK1 inhibition by fasudil effectively inhibits proliferation and promotes polyploidization of megakaryoblasts.
- Fasudil demonstrates therapeutic potential for AMKL by reducing disease burden and enhancing cell differentiation.
- Fasudil represents a promising novel therapeutic agent for clinical AMKL treatment, potentially in combination therapies.
